Search
for
Sort by
Research 61–90 of 68
- Peer Review #3 of "Computational drug repositioning based on side-effects mined from social media (v0.1)"
- Peer Review #3 of "Computational drug repositioning based on side-effects mined from social media (v0.3)"
- Peer Review #2 of "Computational drug repositioning based on side-effects mined from social media (v0.1)"
- Peer Review #2 of "Computational drug repositioning based on side-effects mined from social media (v0.2)"
- Peer Review #1 of "Computational drug repositioning based on side-effects mined from social media (v0.1)"
- Peer Review #3 of "Computational drug repositioning based on side-effects mined from social media (v0.2)"
- Transforming 300 billion points of data into diagnostics, therapeutics and new insights into disease
- The Anti-atopic Lotions Containing Fucoidan Extracted from Ecklonia Cava Impact on Hairless Mice Atopic Dermatitis Skin
- Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review
- 76708 Risk of Developing Scarring and Non-Scarring Alopecia with GLP-1 and GLP-1/GIP Agonist Utilization
- Associations Between GLP‐1 Receptor Agonists and Alopecia: A Multi‐Centre Retrospective Analysis and Public Interest Trends
- The Clinical Center’s Blood Glucose Management Service
- A Systematic Review of the Cutaneous Adverse Effects of GLP-1 Agonists
- Role of Sodium–Glucose Cotransporter-2 Inhibitors in Managing Polycystic Ovary Syndrome: A Systematic Review
- Increased Incidence and Risk of Hair Loss with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Multicentre Cohort Study
- Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review
- Polycystic ovary syndrome: Pathophysiology, Symptoms, Risk factors, and Pharmacological treatment
- How to diagnose a lipodystrophy syndrome
- When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome?
- Overexpression of IL-18 in the Proliferative Phase Endometrium of Patients With Polycystic Ovary Syndrome
- Glycolytic Dysfunction in Granulosa Cells and Its Contribution to Metabolic Dysfunction in Polycystic Ovary Syndrome
- Debatable Topics in PCOS Patients
- Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons
- A review on PCOS: Its causes, symptoms, pathogenesis and management
- Caring for women with polycystic ovary syndrome
- Polycystic ovary syndrome: An update on diagnosis and management
- Semaglutide and the Skin: An Overview of Current Evidence
- Real-world pharmacovigilance insights into drug-induced risk of alopecia
- Polycystic Ovary Syndrome: A Complex Interplay of Hormones and Metabolism
- Antidiabetic Management Strategies for Treatment of Polycystic Ovarian Syndrome